Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy

Vaccine

Volumn 29, Issue 51, 2011, Pages 9521-9528

  Boccalini, Sara ^a   Azzari, Chiara ^b   Resti, Massimo ^b   Valleriani, Claudia ^b   Cortimiglia, Martina ^b   Tiscione, Emilia ^a   Bechini, Angela ^a   Bonanni, Paolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Decision analytic model; Economic evaluation; Pneumococcal diseases; Vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; CHILD; CLINICAL EVALUATION; COHORT ANALYSIS; DISEASE SIMULATION; ECONOMIC EVALUATION; GOVERNMENT; HOSPITALIZATION COST; HOSPITALIZED CHILD; HUMAN; IMMUNIZATION; INFANT; ITALY; MATHEMATICAL MODEL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEPSIS; SEROTYPE; STREPTOCOCCUS PNEUMONIA; TREATMENT OUTCOME; VACCINATION;

CHILD, PRESCHOOL; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; HOSPITALIZATION; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INFANT, NEWBORN; ITALY; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 81955164741     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.013     Document Type: Article

References (41)

1. Prevenar® 13, Pfizer Vaccines. Riassunto delle caratteristiche del prodotto (25.02.2011). European Medicines Agency (EMEA). Disponibile a: http://www.ema.europa.eu/.
2. Piano Nazionale Vaccini 2005-2007. Ministero della Salute Available at: http://www.salute.gov.it/imgs/C_17_pubblicazioni_543_allegato.pdf.
3. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(January (1)):32-41.
4. Poehling K.A., Talbot T.R., Griffin M.R., Craig A.S., Whitney C.G., Zell E., et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006, 295(April (14)):1668-1674.
5. Steenhoff A.P., Shah S.S., Ratner A.J., Patil S.M., McGowan K.L. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis 2006, 42(April (7)):907-914.
6. Durando P., Crovari P., Ansaldi F., Sticchi L., Sticchi C., Turello V., et al. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria region, Italy. Vaccine 2009, 27(May (25-26)):3459-3462.
7. Centers for Disease Control and Prevention (CDC) Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine, United States, 2007. MMWR Morb Mortal Wkly Rep 2010, 59(March (9)):253-257.
8. Isaacman D.J., McIntosh E.D., Reinert R.R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010, 14(March (3)):e197-e209.
9. Chuck A.W., Jacobs P., Tyrrell G., Kellner J.D. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine 2010, July (28)(33):5485-5490.
10. Rozenbaum M.H., Sanders E.A., van Hoek A.J., Jansen A.G., van der Ende A., van den Dobbelsteen G., et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13-valent vaccines. BMJ 2010, 340(June):c2509.
11. Mantovani L.G., de Portu S., Cortesi P.A., Belisari A. Valutazione economica del vaccino coniugato 13-valente. Ital J Public Health 2010, 7(2):S36-S45.
12. WHO Pneumococcal conjugate vaccine for childhood immunisation: position paper. Wkly Epidemiol Rep 2007, 12(82):93-104.
13. Indicazioni in merito alla somministrazione del vaccino Antipneumococcico Prevenar 13 in età pediatrica. Circolare del 27 Maggio 2010, Ministero della Salute.
14. Popolazione residente nella Provincia di Firenze al 1° Gennaio 2010, suddivisa per fascia di età. Demo.istat. Demografia in cifre. Istituto Nazionale di Statistica. Available at: http://demo.istat.it/.
15. Azzari C., Moriondo M., Indolfi G., Massai C., Becciolini L., de Martino M., et al. Molecular detection methods and serotyping performed directly on clinical samples improve diagnostic sensitivity and reveal increased incidence of invasive disease by Streptococcus pneumoniae in Italian children. J Med Microbiol 2008, 57(October (Pt 10)):1205-1212.
16. Resti M., Moriondo M., Cortimiglia M., Indolfi G., Canessa C., Becciolini L., et al. Community-acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real-time polymerase chain reaction using blood samples. Clin Infect Dis 2010, 51(November (9)):1042-1049.
17. MacIntyre C.R., McIntyre P.B., Cagney M. Community-based estimates of incidence and risk factors for childhood pneumonia in Western Sydney. Epidemiol Infect 2003, 131(December (3)):1091-1096.
18. Sinaniotis C.A., Sinaniotis A.C. Community-acquired pneumonia in children. Curr Opin Pulm Med 2005, 11(May (3)):218-225.
19. Juvén T., Mertsola J., Waris M., Leinonen M., Meurman O., Roivainen M., et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000, 19(April (4)):293-298.
20. Virkki R., Juven T., Rikalainen H., Svedström E., Mertsola J., Ruuskanen O. Differentiation of bacterial and viral pneumonia in children. Thorax 2002, 57(May (5)):438-441.
21. Michelow I.C., Olsen K., Lozano J., Rollins N.K., Duffy L.B., Ziegler T., et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004, 113(April (4)):701-707.
22. Giorgi-Rossi P., Merito M., Borgia P. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy. Health Policy 2009, 89(February (2)):225-238.
23. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19(March (3)):187-195.
24. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21(September (9)):810-815.
25. Azzari C., Massai C., Poggiolesi C., Indolfi G., Spagnolo G., De Luca M., et al. Cost of varicella-related hospitalisations in an Italian paediatric hospital: comparison with possible vaccination expenses. Curr Med Res Opin 2007, 23(December (12)):2945-2954.
26. Grimprel E., Laudat F., Baker S.A., Sekaran C., Gruber W.C., Scott D.A. Safety ad immunogenicity of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccination to healthy children in France. Abstracts of the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2009.
27. Capri S., Bamfi F., Marocco A., Demarteau N. Impatto clinico ed economico della vaccinazione anti-HPV. Ital J Public Health 2007, 4(2):S36-S54.
28. Hausdorff W.P. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur J Pediatr 2002, 161(December (Suppl. 2)):S135-S139.
29. D'Ancona F., Salmaso S., Barale A., Boccia D., Lopalco P.L., Rizzo C., et al. Incidence of vaccine preventable pneumococcal invasive infections and blood culture practices in Italy. Vaccine 2005, 23(March (19)):2494-2500.
30. Boonacker C.W., Broos P.H., Sanders E.A., Schilder A.G., Rovers M.M. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review. Pharmacoeconomics 2011, 29(March (3)):199-211.
31. Wolleswinkel-van den Bosch J.H., Stolk E.A., Francois M., Gasparini R., Brosa M. The health care burden and societal impact of acute otitis media in seven European countries: results of an Internet survey. Vaccine 2010, 28(November (Suppl. 6)):G39-G52.
32. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
33. Centers for Disease Control and Prevention, 2005. Available from: http://www.cdc.gov/nchs/hus/previous.htm%23editions.
34. Black S., Shinefield H., Baxter R., Austrian R., Elvin L., Hansen J., et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 2006, 24(Suppl 2). S2-79-80.
35. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294:2043-2051.
36. Metlay J.P., Fishman N.O., Joffe M., Edelstein P.H. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 2006, 24:468-475.
37. Picazo J., Gil de Miguel A., Mendez C., Guijarro P., Garcia L. Budget impact model for Catch Budgetimpact-up program with 13 valent pneumococcal conjugate vaccine in children under 5 years old in the Autonomous Region of Madrid (MR). International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual European Congress 2010.
38. Azzari C., Cortimiglia M., Moriondo M., Canessa C., Lippi F., Ghiori F., et al. Pneumococcal DNA is not detectable in the blood of healthy carrier children. J Med Microbiol 2011, 60(June (Pt 6)):710-714.
39. D'Ancona F., Alfonsi V., Ciofi degli Atti M.L. Survey on vaccination strategies used in different Italian Regions, for the 7-valent conjugate pneumococcal, meningococcal C and varicella vaccines. Ig Sanita Pubbl 2006, 62(September-October (5)):483-492.
40. ® nel contesto di cura italiano. Ital J Public Health 2010, 7(2):S46-S60.
41. Calendario Vaccini della Regione Toscana. Aggiornamento direttive regionali in materia di vaccinazioni. Revoca delibere n. 1249 del 24/11/2003, n.379 del 7/3/2005 e n.1060 del 10/10/2000. Modifi{ligature}ca delibera n. 1386 del 17/12/2001.Bollettino Ufficiale della regione Toscana del 9 gennaio 2008, Parte seconda.